SureFection Technology for High-Throughput Primary Cell Transfection

使用人原代细胞（来自健康供体或患者）作为生理学-或 疾病相关模型在基础研究中具有显著优势， 用于理解和治疗各种人类疾病的治疗发展， 包括癌症、心血管疾病和炎性疾病。不幸的是， 珍贵的原代细胞在很大程度上受到缺乏有效的转染方法的阻碍， 副作用最小，特别是在高通量模式下。我们的建议是， 旨在解决这一关键的未满足需求。我们的第一阶段研究已经证明 我们的技术在分离原代细胞方面比现有方法优越上级， 尤其是完全分化的原代细胞单层。第二阶段的工作拟 开发96孔高通量转染系统，并进一步验证其 在扩展的原代培养中的适用性，包括贴壁和悬浮细胞。 该项目的成功将对基础研究和治疗产生重大影响。 通过扩大原代细胞的效用来开发，原代细胞是最好的体外模型 变成人类

Use of human primary cells (from health donors or patients) as physiology- or disease-relevant models provides significant advantages in basic research and therapeutic development for understanding and treating various human diseases, including cancer, cardiovascular and inflammatory diseases. Unfortunately, utility of precious primary cells is largely hindered by lack of effective means for transfection with minimal side effects, particularly in high-throughput mode. Our proposal is specifically designed to address this critical unmet need. Our Phase I studies have demonstrated that our technology is superior than existing methods in transfecting primary cells, especially fully differentiated primary cell monolayers. Phase II work is proposed to develop a 96-well high-throughput transfection system, and to further validate its applicability in extended primary cultures, including both adherent and suspension cells. Success in this project would have notable impact on basic research and therapeutic development by expanding the utility of primary cells, which are the best in vitro models to human.